Lymphoma is one of the most common malignant tumors in dogs. While traditional chemotherapy offers some effectiveness, its cure rate still leaves room for improvement. In recent years, the combination of Half Body Irradiation (HBI) with chemotherapy has marked a breakthrough in clinical oncology for dogs.
🔬 Key Research Findings: Median progression-free survival:
• HBI + chemotherapy: 1,143 days
• Chemotherapy only: 316 days
Median overall survival:
• HBI + chemotherapy: 1,924 days
• Chemotherapy only: 566 days
Lymphocytes are highly sensitive to radiation, with up to 99% of cancer cells in the irradiated area being eliminated.
💡 Clinical Advantages:
✅ Significantly prolongs progression-free survival
✅ Increases cure rate from traditional 10% to 35–40%
✅ Avoids damage to the hematopoietic system caused by full-body irradiation
If lymphocytes are so sensitive to radiation, wouldn’t full-body irradiation be even more effective?
While full-body irradiation is theoretically possible, it requires bone marrow transplantation to restore hematopoietic function. Half Body Irradiation, on the other hand, delivers treatment in stages, balancing effectiveness with safety.
This therapy offers pet owners a new treatment option. For further information on canine lymphoma therapies, you’re welcome to consult our veterinary oncology specialists.
